Abstract
The ability to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is a foundational component of Canada's containment and mitigation strategies. Laboratory confirmation of COVID-19 cases allows the appropriate clinical management and public health interventions. Whether the local goal is containment or mitigation will depend on local epidemiology of the pandemic. The Respiratory Virus Infections Working Group of the Canadian Public Health Laboratory Network has developed comprehensive Best Practice Guidelines for detection of SARS-CoV-2. Best practices for specimen collection, transportation, testing and biosafety are addressed from the perspective of Canadian public health laboratories to ensure a consistent approach across the country: Population-based testing for COVID-19 should initially be carried out for surveillanceNasopharyngeal swab is the specimen of choice for routine testingNucleic acid amplification tests (such as real-time reverse transcription polymerase chain reaction) are the method of choice for routine testing of SARS-CoV-2The decentralization of nucleic acid amplification testing for COVID-19 to hospital or other high complexity medical laboratories should be promoted to increase test capacity and meet increased demandsIn the early stages of the pandemic, positive (approximately 10-20) and negative (approximately 50) tests by a provincial laboratory require confirmation at the National Microbiology LaboratoryCo-circulation of other viral agents associated with influenza-like Illnesses (e.g. influenza A and B and respiratory syncytial virus) should be monitored as capacity permits, as part of ongoing surveillanceOnce validated, serological testing may be utilized for assessing the presence/absence of immune response to the SARS-CoV-2 at either the population or individual level for select indications, but is likely to be of limited utility in diagnosis of acute COVID-19 illness These recommendations will be updated as new information becomes available.
Highlights
Since the report of the novel coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 in late December 2019 in Wuhan, Hubei Province of China, the vast majority of countries have reported laboratory-confirmed cases of COVID-19
SARS-CoV-2 in patients is critical for surveillance, diagnosis and clinical management of persons presenting with acute respiratory illness (ARI), influenza-like illness (ILI) and severe respiratory illness to support Canada’s containment and mitigation strategies
The purpose of SARS-CoV-2 testing can fall into two broad categories, and will depend on the local epidemiology and goals of public health strategies: 1) Testing for the purpose of high probability case finding among persons presenting with ARI and ILI and appropriate exposure criteria is critical to ensure COVID-19 cases are identified in a timely fashion to ensure appropriate clinical and public health management can occur during the containment phase of the pandemic
Summary
Since the report of the novel coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 in late December 2019 in Wuhan, Hubei Province of China, the vast majority of countries have reported laboratory-confirmed cases of COVID-19. The clinical presentation of COVID-19, which is caused by SARS-CoV-2, is non-specific and overlaps with other seasonal respiratory viruses, including influenza.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Canada communicable disease report = Releve des maladies transmissibles au Canada
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.